e-learning
resources
Stockholm 2007
Sunday 16.09.2007
Pulmonary infections and inflammation
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Comparisom between imipenem/cilastatin and cefepim for treatment of severe nosocomial pneumonia
A. Eatemadi, E. Eidani, M. Jahangirnejad, F. Soltani (Ahwaz, Islamic Republic Of Iran)
Source:
Annual Congress 2007 - Pulmonary infections and inflammation
Session:
Pulmonary infections and inflammation
Session type:
Electronic Poster Discussion
Number:
479
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Eatemadi, E. Eidani, M. Jahangirnejad, F. Soltani (Ahwaz, Islamic Republic Of Iran). Comparisom between imipenem/cilastatin and cefepim for treatment of severe nosocomial pneumonia. Eur Respir J 2007; 30: Suppl. 51, 479
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Treatment of nosocomial pneumonia with piperacillin-tazobactam
Source: Eur Respir J 2007; 30: Suppl. 51, 53s
Year: 2007
The use of piperacillin/tazobactam for treatment of pneumonia in neutropenic patients
Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations
Year: 2010
New antibiotics for VAP
Source: Eur Respir Mon 2011; 53: 48-53
Year: 2011
Efficacy and safety of levofloxacin treatment of community-acquired pneumonia in hospitalized patients
Source: Eur Respir J 2005; 26: Suppl. 49, 637s
Year: 2005
Ertapenem therapy for community-acquired pneumonia in the elderly
Source: Eur Respir J 2005; 26: Suppl. 49, 638s
Year: 2005
Antibiotic treatment for nosocomial pneumonia
Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=211
Year: 2004
Tigecycline vs levofloxacin for the treatment of community-acquired pneumonia (CAP): EU experience
Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia
Year: 2008
Use of respiratory fluoroquinolones gatifloxacin for treatment of severe community-acquired pneumonia (SCAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 166s
Year: 2006
Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia
Source: Eur Respir J 2010; 36: 128-134
Year: 2010
Comparison of conventional and sequential antibiotic therapy of community-acquired pneumonia with levofloxacin and moxifloxacin
Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia
Year: 2007
Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia
Source: Eur Respir Rev 2007; 16: 33-39
Year: 2007
Efficacy and safety of azithromycin vs. clarithromycin for the treatment of community-acquired pneumonia due to
legionella pneumophila
Source: Annual Congress 2004 - Community acquired pneumonia - epidemiology and host defence
Year: 2004
Ventilator-associated pneumonia due to colistin susceptible-only microorganisms
Source: Eur Respir J 2007; 30: 307-313
Year: 2007
Pharmacokinetic optimisation of β-lactams for the treatment of ventilator-associated pneumonia
Source: Eur Respir Rev 2007; 16: 45-49
Year: 2007
Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia
Source: Eur Respir J 2004; 24 : 644-648
Year: 2004
Delirium induced by clarithromycin in a patient with community-acquired pneumonia
Source: Eur Respir J 2006; 28: 671-672
Year: 2006
Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia
Source: Eur Respir J 2009; 33: 153-159
Year: 2009
The approach to antibiotic treatment in community-acquired pneumonia
Source: Annual Congress 2008 - MP14 - The approach to antibiotic treatment in community-acquired pneumonia
Year: 2008
Anti-Pseudomonas antibiotic use for hospitalized patients with community-acquired pneumonia
Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept